SCHEMBL3603144

SCHEMBL3603144

Brc1ccc(-c2nc(-c3ccccc3)cs2)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.75
KDM4E B2RXH2 8/20 0.75
SMN1; SMN2 Q16637 8/20 0.75
LMNA P02545 4/20 0.75
SREBF2 Q12772 1/20 0.70
CYP19A1 P11511 2/20 0.69
KMT2A Q03164 7/20 0.69
AR P10275 1/20 0.69
NPC1 O15118 6/20 0.64
MAPT P10636 7/20 0.59
MEN1 O00255 6/20 0.59
ALDH1A1 P00352 4/20 0.59
GAA P10253 2/20 0.59
POLB P06746 1/20 0.59
PKM P14618 1/20 0.59
HPGD P15428 1/20 0.59
ALOX12 P18054 1/20 0.59
NPSR1 Q6W5P4 2/20 0.55
CASP3 P42574 1/20 0.54
SENP8 Q96LD8 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17336836 1.00 RAB9A (0.75) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL11213828 0.91 SREBF2 (0.82) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL11212983 0.91 SREBF2 (0.82) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL11215130 0.91 SREBF2 (0.82) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL11464717 0.89 SREBF2 (0.79) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL2781370 0.89 KDM4E (0.85) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL7532072 0.84 KDM4E (0.73) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL26123239 0.84 KDM4E (0.73) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL26118261 0.84 KDM4E (0.73) RAB9AKDM4ESMN1; SMN2LMNASREBF2
SCHEMBL28493960 0.84 SMN1; SMN2 (0.73) RAB9AKDM4ESMN1; SMN2LMNASREBF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101265258-B Organic material and application thereof in organic electroluminescence device UNIV TSINGHUA 2011-03-30 CN disclosed
CN-101663298-A Thiazole derivatives as modulators of g protein-coupled receptors IRM LLC 2010-03-03 CN disclosed
US-20100022592-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-01-28 US disclosed
US-20100022592-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2010-01-28 US disclosed
EP-2121675-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2009-11-25 EP disclosed
CN-101265258-A Organic material and application thereof in organic electroluminescence device UNIV TSINGHUA (CN) 2008-09-17 CN disclosed
WO-2008103500-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS IRM LLC (BM) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022592-A1 THIAZOLE DERIVATIVES AS MODULATORS OF G PROTEIN-COUPLED RECEPTORS GPR119, GPR65, GPR180 RAB9A 2377/4885KDM4E 4170/4885SMN1; SMN2 4681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.